In a remarkable display of community spirit and commitment to cancer research, Fred's Team has set a historic fundraising record by raising over $10 million in a single year. This achievement, celebrated during their 30th anniversary, underscores the dedication of runners, donors, and supporters to advancing cancer research at the prestigious Memorial Sloan Kettering Cancer Center (MSK). The funds raised will significantly bolster ongoing research initiatives, paving the way for innovative treatments and improved patient outcomes.

A Legacy of Commitment to Cancer Research

Since its inception in 1995, Fred's Team has directed more than $130 million to MSK, with every dollar raised going directly to support groundbreaking research. This commitment has contributed to significant advancements in cancer treatment and care. The success of the 2025 fundraising campaign is a testament to the strong community backing that Fred's Team has cultivated over three decades, showcasing the power of collective action in the fight against cancer. Dr. Sarat Chandarlapaty, a specialist in breast cancer at MSK, highlighted the evolution of cancer care since the program's founding. He noted that when Fred's Team was established, many modern treatments, including immunotherapy and precision oncology, were still in their infancy. The funds raised will enable continued exploration into new therapeutic avenues, which could lead to breakthroughs that transform the landscape of cancer treatment.

Impactful Research Initiatives Supported by Fred's Team

The funds generated by Fred's Team have enabled a range of significant research initiatives that have improved survival rates and treatment options for cancer patients. Notable advancements include: - Childhood Leukemia Treatments: Research funded by Fred's Team has played a crucial role in developing innovative chemotherapy regimens and stem cell transplantation methods. These advances have dramatically increased the five-year survival rate for children diagnosed with acute lymphoblastic leukemia (ALL) from under 10% in the 1970s to nearly 90% today. - Immunotherapy Breakthroughs: A clinical trial of the immunotherapy drug dostarlimab (Jemperli®) for a rare subtype of rectal cancer yielded astonishing results, with all participants experiencing complete remission without the need for surgery. This groundbreaking outcome is set to redefine treatment protocols for patients with this specific cancer type. - Targeted Therapies for Brain Tumors: The recent FDA approval of vorasidenib (Voranigo®), the first targeted drug for low-grade gliomas with an IDH gene mutation, marks a significant milestone. This development represents the first new treatment option for this type of brain tumor in over two decades, providing new hope for patients under age 50.

The Role of AI in Cancer Research: A New Frontier

As cancer research continues to evolve, the integration of artificial intelligence (AI) into oncology is becoming increasingly significant. AI technologies are aiding researchers in analyzing vast datasets, identifying patterns, and predicting treatment responses, which can enhance the precision and effectiveness of cancer therapies. For instance, tools like MSK-IMPACT® can detect genetic mutations linked to cancer, allowing for more tailored treatment plans that align with individual patient profiles. The funding raised by Fred's Team will contribute to the expansion of such innovative research, which is crucial in the era of precision oncology. As scientists harness AI's capabilities, the potential for breakthroughs in early detection, personalized treatment strategies, and improved patient outcomes grows exponentially.

A Community United in Purpose

Fred's Team, named in honor of Fred Lebow, a co-founder of the New York City Marathon, continues to inspire participants to run not just for fitness, but for a cause that transcends personal achievement. Together, over 1,200 runners, including MSK staff and cancer survivors, participated in the 2025 events, reinforcing the notion that collective efforts can lead to monumental change. The camaraderie displayed at events like the TCS New York City Marathon serves as a powerful reminder of the impact that community support can have on advancing cancer research. Christine Burke, Chief Commercial Officer of New York Road Runners, emphasized the importance of partnerships like that of Fred's Team and the New York Road Runners, stating that their collaboration not only raises essential funds but also inspires individuals to run for a greater purpose.

Conclusion: A Future Full of Hope

The unprecedented $10 million raised by Fred's Team is a beacon of hope for cancer patients and their families. As MSK continues to advance its research initiatives, the potential for new treatments and improved patient care expands. This remarkable achievement illustrates the power of community engagement in the fight against cancer and emphasizes the importance of ongoing support for cancer research. For those interested in staying informed about the latest developments in AI and cancer research, resources like CureCancerWithAi.com offer valuable insights and updates on the intersection of technology and oncology. The journey toward innovative cancer treatment continues, fueled by the collective efforts of dedicated individuals and organizations committed to making a difference.

Readers who want more plain-language context on AI and oncology can also explore the Cure Cancer With AI blog and learn more about the project.